Effects of aloe polysaccharide, a polysaccharide extracted from Aloe vera, on TNF‑α‑induced HaCaT cell proliferation and the underlying mechanism in psoriasis

Leng,Hong; Pu,Li; Xu,Longjiang; Shi,Xin; Ji,Jiang; Chen,Kun

doi:10.3892/mmr.2018.9319

Effects of aloe polysaccharide, a polysaccharide extracted from Aloe vera, on TNF‑α‑induced HaCaT cell proliferation and the underlying mechanism in psoriasis

Authors:
- Hong Leng
- Li Pu
- Longjiang Xu
- Xin Shi
- Jiang Ji
- Kun Chen
View Affiliations

Affiliations: Dermatological Department, Jiangsu Provincial Key Laboratory of Molecular Biology for Skin Disease and STIs, The Second Affiliated Hospital of Soochow University, Nanjing, Jiangsu 210042, P.R. China
Published online on: July 25, 2018 https://doi.org/10.3892/mmr.2018.9319
Pages: 3537-3543

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Aloe vera is a traditional wound‑healing medicine used for the treatment of skin disorders. Aloe polysaccharide (APS) is the main macromolecule of Aloe vera, which contributes to its function. Psoriasis is an immune‑mediated chronic inflammatory disease, which affects 2‑3% of the general population. The conventional remedies used to treat psoriasis demonstrate limited effects; therefore, natural products, including Aloe vera, are being taken into consideration. However, the effects of APS on the treatment of psoriasis and the underlying mechanisms remain to be elucidated. The human keratinocyte cell line HaCaT was used to determine the effects of APS on psoriasis. Cells were randomly divided into five groups: i) Negative control group; ii) tumor necrosis factor (TNF)‑α stimulated psoriasis model group; and iii) APS (20, 40 and 80 µg/ml) pretreated psoriasis groups. Cell viability and proliferation were investigated using the CCK‑8 assay. ELISA and western blotting were applied to study the abundance of interleukin (IL)‑8 and IL‑12 in TNF‑α‑incubated culture medium and APS‑treated HaCaT cells, respectively. In addition, the mRNA expression levels of p65, and the protein expression levels of nuclear factor (NF)‑κB inhibitor‑α (IκBα) and phosphorylated‑p65, were detected by reverse transcription‑quantitative polymerase chain reaction and western blotting, respectively. APS was revealed to significantly reduce TNF‑α‑stimulated elevation of HaCaT cell proliferation in a dose‑dependent manner. The expression levels of inflammatory factors, including IL‑8 and IL‑12, were increased in response to TNF‑α. In addition, the mRNA and protein expression levels of p65 were increased following treatment with TNF‑α. Notably, treatment with APS was demonstrated to significantly attenuate the aforementioned effects in a dose‑dependent manner. Furthermore, IκBα protein expression levels were significantly reduced following treatment with TNF‑α, which was significantly reversed following treatment with APS. In conclusion, these results suggested that APS inhibited TNF‑α‑induced proliferation of keratinocytes and overactivation of the NF‑κB signaling pathway.

View Figures

View References

1	Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, et al: Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 58:826–850. 2008. View Article : Google Scholar : PubMed/NCBI
2	Lin AM, Rubin CJ, Khandpur R, Wang JY, Riblett M, Yalavarthi S, Villanueva EC, Shah P, Kaplan MJ and Bruce AT: Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol. 187:490–500. 2011. View Article : Google Scholar : PubMed/NCBI
3	Carey W, Glazer S, Gottlieb AB, Lebwohl M, Leonardi C, Menter A, Papp K, Rundle AC and Toth D: Relapse, rebound, and psoriasis adverse events: An advisory group report. J Am Acad Dermatol. 54 4 Suppl 1:S171–S181. 2006. View Article : Google Scholar : PubMed/NCBI
4	Menter A and Griffiths CE: Current and future management of psoriasis. Lancet. 370:272–284. 2007. View Article : Google Scholar : PubMed/NCBI
5	Sala M, Elaissari A and Fessi H: Advances in psoriasis physiopathology and treatments: Up to date of mechanistic insights and perspectives of novel therapies based on innovative skin drug delivery systems (ISDDS). J Control Release. 239:182–202. 2016. View Article : Google Scholar : PubMed/NCBI
6	Choonhakarn C, Busaracome P, Sripanidkulchai B and Sarakarn P: A prospective, randomized clinical trial comparing topical aloe vera with 0.1% triamcinolone acetonide in mild to moderate plaque psoriasis. J Eur Acad Dermatol Venereol. 24:168–172. 2010. View Article : Google Scholar : PubMed/NCBI
7	Das S, Mishra B, Gill K, Ashraf MS, Singh AK, Sinha M, Sharma S, Xess I, Dalal K, Singh TP and Dey S: Isolation and characterization of novel protein with anti-fungal and anti-inflammatory properties from Aloe vera leaf gel. Int J Biol Macromol. 48:38–43. 2011. View Article : Google Scholar : PubMed/NCBI
8	Davis RH, DiDonato JJ, Johnson RW and Stewart CB: Aloe vera, hydrocortisone, and sterol influence on wound tensile strength and anti-inflammation. J Am Podiatr Med Assoc. 84:614–621. 1994. View Article : Google Scholar : PubMed/NCBI
9	Baradaran A, Nasri H, Nematbakhsh M and Rafieian-Kopaei M: Antioxidant activity and preventive effect of aqueous leaf extract of Aloe Vera on gentamicin-induced nephrotoxicity in male Wistar rats. Clin Ter. 165:7–11. 2014.PubMed/NCBI
10	Seyger MM, van de Kerkhof PC, van Vlijmen-Willems IM, de Bakker ES, Zwiers F and de Jong EM: The efficacy of a new topical treatment for psoriasis: Mirak. J Eur Acad Dermatol Venereol. 11:13–18. 1998. View Article : Google Scholar : PubMed/NCBI
11	Paulsen E, Korsholm L and Brandrup F: A double-blind, placebo-controlled study of a commercial Aloe vera gel in the treatment of slight to moderate psoriasis vulgaris. J Eur Acad Dermatol Venereol. 19:326–331. 2005. View Article : Google Scholar : PubMed/NCBI
12	Yarilina A, Park-Min KH, Antoniv T, Hu X and Ivashkiv LB: TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon-response genes. Nat Immunol. 9:378–387. 2008. View Article : Google Scholar : PubMed/NCBI
13	Gibellini L, De Biasi S, Bianchini E, Bartolomeo R, Fabiano A, Manfredini M, Ferrari F, Albertini G, Trenti T, Nasi M, et al: Anti-TNF-α drugs differently affect the TNFα-sTNFR system and monocyte subsets in patients with psoriasis. PLoS One. 11:e01677572016. View Article : Google Scholar : PubMed/NCBI
14	Miroddi M, Navarra M, Calapai F, Mancari F, Giofrè SV, Gangemi S and Calapai G: Review of clinical pharmacology of Aloe vera L. in the treatment of psoriasis. Phytother Res. 29:648–655. 2015. View Article : Google Scholar : PubMed/NCBI
15	Dhanabal SP, Dwarampudi Priyanka L, Muruganantham N and Vadivelan R: Evaluation of the antipsoriatic activity of Aloe vera leaf extract using mouse tail model psoriasis. Phytother Res. 26:617–619. 2012. View Article : Google Scholar : PubMed/NCBI
16	Baldwin AS Jr: The NF-kappa B and I kappa B proteins: New discoveries and insights. Annu Rev Immunol. 14:649–683. 1996. View Article : Google Scholar : PubMed/NCBI
17	Tak PP and Firestein GS: NF-kappaB: A key role in inflammatory diseases. J Clin Invest. 107:7–11. 2001. View Article : Google Scholar : PubMed/NCBI
18	Hayden MS and Ghosh S: Signaling to NF-kappaB. Genes Dev. 18:2195–2224. 2004. View Article : Google Scholar : PubMed/NCBI
19	Lizzul PF, Aphale A, Malaviya R, Sun Y, Masud S, Dombrovskiy V and Gottlieb AB: Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J Invest Dermatol. 124:1275–1283. 2005. View Article : Google Scholar : PubMed/NCBI
20	Vijayalakshmi D, Dhandapani R, Jayaveni S, Jithendra PS, Rose C and Mandal AB: In vitro anti inflammatory activity of Aloe vera by down regulation of MMP-9 in peripheral blood mononuclear cells. J Ethnopharmacol. 141:542–546. 2012. View Article : Google Scholar : PubMed/NCBI
21	Lima JF, Carvalho J, Pinto-Ribeiro I, Almeida C, Wengel J, Cerquera L, Figueiredo C, Oliveira C and Azevedo NF: Targeting miR-9 in gastric cancer cells using locked nucleic acid oligonucleotides. BMC Mol Biol. 19:62018. View Article : Google Scholar : PubMed/NCBI
22	Mizuno K, Morizane S, Takiguchi T and Iwatsuki K: Dexamethasone but not tacrolimus suppresses THF-α-induced thymic stromal lymphopoitin expression in lesional keratinocytes of atopic dermatitis model. J Dermatol Sci. 80:45–53. 2015. View Article : Google Scholar : PubMed/NCBI
23	Kyle S, Chandler D, Griffiths CE, Helliwell P, Lewis J, McInnes I, Oliver S, Symmons D and McHugh N: British Society for Rheumatology Standards Guidelines Audit Working Group (SGAWG): Guideline for anti-TNF-alpha therapy in psoriatic arthritis. Rheumatology (Oxford). 44:390–397. 2005. View Article : Google Scholar : PubMed/NCBI
24	Lowes MA, Bowcock AM and Krueger JG: Pathogenesis and therapy of psoriasis. Nature. 445:866–873. 2007. View Article : Google Scholar : PubMed/NCBI
25	Yan S, Xu Z, Lou F, Zhang L, Ke F, Bai J, Liu Z, Liu J, Wang H, Zhu H, et al: NF-κB-induced microRNA-31 promotes epidermal hyperplasia by repressing protein phosphatase 6 in psoriasis. Nat Commun. 6:76522015. View Article : Google Scholar : PubMed/NCBI
26	Deng S, May BH, Zhang AL, Lu C and Xue CC: Plant extracts for the topical management of psoriasis: A systematic review and meta-analysis. Br J Dermatol. 169:769–782. 2013. View Article : Google Scholar : PubMed/NCBI
27	Sato K, Takaishi M, Tokuoka S and Sano S: Involvement of TNF-α converting enzyme in the development of psoriasis-like in a mose model. PLoS One. 9:e1124082014. View Article : Google Scholar : PubMed/NCBI
28	Gudjonsson JE, Johnston A, Sigmundsdottir H and Valdimarsson H: Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol. 135:1–8. 2004. View Article : Google Scholar : PubMed/NCBI
29	Sidhom E, Pilmane M and Kisis J: Local antimicrobial, protease and cytokine defense systems in psoriatic skin. Indian J Dermatol Venereol Leprol. 82:284–291. 2016. View Article : Google Scholar : PubMed/NCBI
30	Kauffman CL, Aria N, Toichi E, McCormick TS, Cooper KD, Gottlieb AB, Everitt DE, Frederick B, Zhu Y, Graham MA, et al: A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol. 123:1037–1044. 2004. View Article : Google Scholar : PubMed/NCBI
31	Chandel NS, Trzyna WC, McClintock DS and Schumacker PT: Role of oxidants in NF-kappa B activation and TNF-alpha gene transcription induced by hypoxia and endotoxin. J Immunol. 165:1013–1021. 2000. View Article : Google Scholar : PubMed/NCBI
32	Bouwmeester T, Bauch A, Ruffner H, Angrand PO, Bergamini G, Croughton K, Cruciat C, Eberhard D, Gagneur J, Ghidelli S, et al: A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway. Nat Cell Biol. 6:97–105. 2004. View Article : Google Scholar : PubMed/NCBI
33	Baeuerle PA and Henkel T: Function and activation of NF-kappa B in the immune system. Annu Rev Immunol. 12:141–179. 1994. View Article : Google Scholar : PubMed/NCBI
34	Goldminz AM, Au SC, Kim N, Gottlieb AB and Lizzul PF: NF-kappaB: An essential transcription factor in psoriasis. J Dermatol Sci. 69:89–94. 2013. View Article : Google Scholar : PubMed/NCBI